Strand Therapeutics
Strand Therapeutics is a biotechnology company developing programmable, long-acting mRNA therapeutics capable of delivering precise, multi-functional, potentially curative treatments. The company focuses on creating autonomous medicines that activate only in diseased cells, utilizing proprietary genetic circuits and a platform for mRNA programming. Their mission is to transform the lives of patients through targeted, potentially curative therapies, with initial focus on oncology. They leverage synthetic biology, engineering, and chemistry to build innovative mRNA platforms and have a broad pipeline including intratumoral, systemic, and immune cell engineering modalities.
Industries
Nr. of Employees
medium (51-250)
Strand Therapeutics
Cambridge, Massachusetts, United States, North America
Products
STX-001
Intratumoral self-replicating mRNA therapeutic encoding interleukin-12 for the treatment of melanoma, triple-negative breast cancer, and other solid tumors; progressed through IND-enabling and into Phase 1 clinical evaluation.
STX-003
Systemically delivered self-replicating mRNA circuit designed for intravenous non-liver delivery, encoding interleukin-12 for non-small cell lung cancer and other solid tumors; described in preclinical publications and presentations.
STX-004 / STX-005
Circular RNA-based immune cell engineering candidates encoding CAR payloads for hematological malignancies; programs focused on cell therapy applications using circular RNA circuits.
STX-002 / STX-006
Additional programmable mRNA programs in the pipeline with undisclosed indications and payloads, represented at discovery through preclinical/IND-enabling stages.
STX-001
Intratumoral self-replicating mRNA therapeutic encoding interleukin-12 for the treatment of melanoma, triple-negative breast cancer, and other solid tumors; progressed through IND-enabling and into Phase 1 clinical evaluation.
STX-003
Systemically delivered self-replicating mRNA circuit designed for intravenous non-liver delivery, encoding interleukin-12 for non-small cell lung cancer and other solid tumors; described in preclinical publications and presentations.
STX-004 / STX-005
Circular RNA-based immune cell engineering candidates encoding CAR payloads for hematological malignancies; programs focused on cell therapy applications using circular RNA circuits.
STX-002 / STX-006
Additional programmable mRNA programs in the pipeline with undisclosed indications and payloads, represented at discovery through preclinical/IND-enabling stages.
Services
Collaborative research and development partnerships
Opportunities for external partners to collaborate on programmable mRNA programs, preclinical studies, and expansion of therapeutic programs.
Preclinical development and IND-enabling support
Preclinical pharmacology, toxicity, and translational study execution to generate data supporting IND-enabling packages and regulatory submissions.
Process and analytical development for mRNA and LNPs
Process optimization, scale-up support, analytical method development, and assay qualification for mRNA drug substance and LNP drug product development.
Collaborative research and development partnerships
Opportunities for external partners to collaborate on programmable mRNA programs, preclinical studies, and expansion of therapeutic programs.
Preclinical development and IND-enabling support
Preclinical pharmacology, toxicity, and translational study execution to generate data supporting IND-enabling packages and regulatory submissions.
Process and analytical development for mRNA and LNPs
Process optimization, scale-up support, analytical method development, and assay qualification for mRNA drug substance and LNP drug product development.
Expertise Areas
- Programmable mRNA therapeutics
- Synthetic biology and genetic circuits
- Translational biology and preclinical development
- Immuno-oncology
Key Technologies
- Self-replicating mRNA (replicon)
- Circular RNA
- Modified mRNA
- MicroRNA sensor circuits